MediPal Holdings Corporation
Q1 2027 Term Financial Summary (Japan GAAP) (Consolidated)
Sales of 989,503 hundred million yen, up 4.7% YoY; quarterly net income attributable to owners of parent of 13,646 hundred million yen, up 42.3% YoY. By segment, medical pharmaceuticals wholesale is strong, but overall operating income declines to 13,386 hundred million yen. Full-year guidance unchanged. Supplemental earnings materials to be released.
Key Figures
- Sales: 989,503百万円 (YoY +4.7%)
- Operating income: 13,386百万円 (YoY △4.7%)
- Net income attributable to owners of parent (quarter): 13,646百万円 (YoY +42.3%)
AI要約
Overview of results
For the first quarter of the fiscal year ending March 2027, consolidated net sales amounted to 989,503 hundred million yen, up 4.7% YoY. However, operating income was 13,386 hundred million yen, down 4.7% YoY. Gross profit was 65,733 hundred million yen, up 1.6%. By segment, increases in medical pharmaceuticals wholesale contributed to sales growth, while margins in cosmetic and daily living goods wholesale and non-prescription drugs wholesale were pressures that persisted. Supplemental materials will be released.
Full-year outlook and financial position
No changes to the full-year guidance from the time of disclosure. At the end of the first quarter, total assets stood at 1,937.4 hundred million yen (11, size), net assets were 791,716 hundred million yen, and equity ratio was 33.5%. While current assets such as cash and cash equivalents increased, net income for the period may face headwinds due to amortization of goodwill. The accounting treatments related to business combinations have been finalized, and comparative information has been replaced with settled values.
Medipal Holdings Corporation
Company overview · Stock price · Financial data · All IR
